Outcomes Following the Use of Angiotensin II in Patients with Postoperative Vasoplegic Syndrome: A Case Series

Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for...

Descripción completa

Detalles Bibliográficos
Autores principales: Konkol, Samuel B., Morrisette, Matthew J., Hulse, Matthew C., Enfield, Kyle B., Mihalek, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387627/
https://www.ncbi.nlm.nih.gov/pubmed/35799569
http://dx.doi.org/10.4103/aca.aca_98_21
Descripción
Sumario:Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for the treatment of isolated PVS. All patients achieved their MAP goal and the majority showed improvement in lactate and background catecholamine dose; however, variables of perfusion changed discordantly. Three of six patients survived to hospital discharge.

Ejemplares similares